Registry · PRGO

Does Perrigo support Israel?

Perrigo Company plc

Business presence documentedupdated 2026-09-26

Perrigo does business in Israel — we found records of its operations there, but no record of donations, aid, or a public statement of support. Every claim below links to its source.

Filed under: Pharma & healthcare companies · Household & consumer goods brands · Companies that support Israel

Background

Perrigo is a case where the honest answer changes with the date. From 2005 the company was deeply embedded in Israel: the $818 million Agis acquisition made it one of the country's biggest pharmaceutical employers, with a Bnei Brak headquarters, the Yeruham generics plant and the Chemagis API business, and its SEC filings carried a standing risk factor about its 'significant operations in Israel.' It kept investing while it was there: TheMarker and Globes put a roughly four-year expansion of the Yeruham site, crowned by a new plant opened on 2 March 2016, at about NIS 180 million (about $46 million), and in May 2019 Perrigo signed an agreement with the plant's workers and the Histadrut undertaking to keep it in Yeruham for at least five years after the divestiture. Its Israeli arm also ran a run of generic-drug development deals with the Israeli dermatology company Sol-Gel Technologies, the sixth of them announced in December 2018. Perrigo then exited in stages — Chemagis to SK Capital in 2017, and the whole generic prescription business, Israeli plants included, to Altaris in 2021, where it now trades as Padagis. Note that Padagis is an independent company and its Israeli activity should not be attributed to Perrigo. What remains today is a supply relationship: Perrigo still buys raw materials and finished goods from Israeli suppliers for some self-care products. Separately, Perrigo redomiciled to Ireland through its 2013 acquisition of Elan — an Irish, not Israeli, tax matter that is sometimes confused with its Israeli history.

Globes Perrigo Irish Directors' Report Perrigo Company plc annual report (TASE filing) TheMarker (Hebrew) Sol-Gel Technologies press release (SEC Form 6-K, Exhibit 99.1)

Timeline of documented records

2005200820112014201720202005-03 — Acquisition: Agis Industries (1983) Ltd. (Israel)Acquisition2005-032005 — Operations in Israel: Perrigo Israel Pharmaceuticals Ltd. (Bnei Brak headquarters; Yeruham and other plants)Operations in Israel20052016-03 — Investment / program: Perrigo's Yeruham manufacturing site, Negev, IsraelInvestment / program2016-032017-11 — Operations in Israel: Chemagis (Israeli active-pharmaceutical-ingredient business, sold to SK Capital)Operations in Israel2017-112018-12 — Partnership: Sol-Gel Technologies Ltd. (Ness Ziona, Israel)Partnership2018-122019-05 — Operations in Israel: Workers at Perrigo Israel's Yeruham plant and the Histadrut labour federation (Negev region)Operations in Israel2019-052021-07 — Operations in Israel: Padagis LLC / Altaris Capital Partners (buyer of Perrigo's generic Rx business, including the Israeli plants)Operations in Israel2021-07

Documented records

TypeDateAmountRecipientSources
Acquisition2005-03-17$818,000,000Agis Industries (1983) Ltd. (Israel)
Perrigo completed its acquisition of Agis Industries — then the second-largest pharmaceutical company in Israel — on 17 March 2005, in a cash-and-stock deal announced in November 2004 and valued at about $818 million (reported at up to roughly $850 million including assumed debt). The deal brought Perrigo Israeli generic-drug plants, the Chemagis active-pharmaceutical-ingredient business and an Israeli headquarters in Bnei Brak.
Operations in Israel2005—Perrigo Israel Pharmaceuticals Ltd. (Bnei Brak headquarters; Yeruham and other plants)
For roughly sixteen years after the Agis deal Perrigo was one of the largest foreign employers in Israeli pharma. Its annual reports stated plainly that 'we have significant operations in Israel,' listing an Israeli address in Bnei Brak, and its generic plant in the Negev town of Yeruham employed around 850 people.
Investment / program2016-03-02$46,320,000Perrigo's Yeruham manufacturing site, Negev, Israel
Perrigo inaugurated a new drug manufacturing and storage plant at its Yeruham site in Israel's Negev on 2 March 2016. TheMarker described the plant as the central component of a roughly four-year expansion of the site costing about NIS 180 million in all; Globes, reporting the same inauguration from a Reuters interview, put the expansion at some NIS 175 million and headlined it a $46 million factory, and two later Globes reports each described the Yeruham plant as built in 2016 at an investment of NIS 180 million. At the Bank of Israel rate of 3.886 shekels to the dollar that day, NIS 180 million is about $46 million. Perrigo said the programme was expected to add $100 million to annual sales, almost all of it export, and about 200 jobs at the site, of which roughly 150 had been filled; the company then employed about 1,200 people in Israel, some 850 of them at the Yeruham and Neot Hovav operations centres. Perrigo president John Hendrickson said Israel was for the company a vital centre of excellence for continued success in a competitive global environment.
Operations in Israel2017-11-21$110,000,000Chemagis (Israeli active-pharmaceutical-ingredient business, sold to SK Capital)
Perrigo began unwinding its Israeli industrial base in 2017, completing the divestiture of the Israel-based active-pharmaceutical-ingredient business it had gained with Agis — Chemagis — to New York investment firm SK Capital for $110 million. Israeli coverage put the wider package of Israeli assets sold that year at about $130 million.
Partnership2018-12-04—Sol-Gel Technologies Ltd. (Ness Ziona, Israel)
On 4 December 2018 the Israeli dermatology company Sol-Gel Technologies, of Ness Ziona, announced a sixth collaboration agreement with Perrigo Israel — the release, filed with the SEC on Form 6-K, calls it an affiliate of Perrigo Company plc, while TheMarker described it as wholly owned by Perrigo — to develop, manufacture and commercialise a generic topical product. Perrigo was to seek approval from the US Food and Drug Administration and, if it was granted, to commercialise the product in the United States; the two companies were to share the development costs and the gross profits from sales. No value was disclosed, so no amount is recorded here. The release noted that an earlier product of the same partnership, ivermectin cream 1%, had received FDA tentative approval in January 2018. TheMarker added that Sol-Gel is controlled by the Israeli pharmaceutical investor Mori Arkin.
Operations in Israel2019-05-20—Workers at Perrigo Israel's Yeruham plant and the Histadrut labour federation (Negev region)
Ahead of selling its generic prescription business, Perrigo signed an agreement on 20 May 2019 with the workers' committee of its Yeruham plant and the Histadrut labour federation, undertaking to keep the plant in Yeruham for at least five years after the sale. The agreement extended the collective labour agreement by two years to April 2022 with staged pay rises, raised the per-employee welfare budget, and gave every employee with at least a year's service a sale bonus of NIS 2,250 for each year of service, which Globes reported was capped at a cumulative NIS 70,000 gross. TheMarker put the plant at 630 employees, Globes at 600. It was signed by Yossi Gal, human-resources manager of Perrigo Israel, with the committee chairman Haim Ben Abu and the Histadrut officials Clarice Vinig and Eliezer Blu. TheMarker reported that the undertaking not to relocate reflected the fact that the only bidders were private-equity funds rather than pharmaceutical companies with existing plants to merge it into; the division was expected to fetch at least $2.5 billion and was sold to Altaris in 2021.
Operations in Israel2021-07-06$1,550,000,000Padagis LLC / Altaris Capital Partners (buyer of Perrigo's generic Rx business, including the Israeli plants)
Perrigo sold its generic prescription pharmaceuticals business to Altaris Capital Partners for $1.55 billion, closing on 6 July 2021; the buyer renamed it Padagis, which today operates sites in the United States and Israel. The sale transferred Perrigo's Israeli manufacturing, including the Yeruham plant, and Globes reported it as ending Perrigo's involvement in Israel. Current status: Perrigo's most recent Irish directors' report describes an Israel relationship reduced to procurement — it 'sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including Omeprazole.'

Frequently asked questions

Did Perrigo donate money to Israel or Israeli causes?

We have no records of donations. What is on record is commercial activity in Israel (Acquisition, Operations in Israel, Investment / program, Partnership), which is not the same as support — see the records on this page.

Where does this information come from?

Every record on this page links to its source — news reports, official company statements, tax filings, or government records. 17 distinct sources are cited for Perrigo. Our methodology page explains the full verification process.

Sources & citations

Record last updated: 2026-09-26

More companies